Top Markets
#1 DogBull DogBull +72.24%
#2 Siren Siren +31.75%
#3 OriginTrail OriginTrail +16.47%
#4 Verus Coin Verus Coin +9.50%
#5 COTI COTI +6.93%
#6 Falcon Finance Falcon Finance +6.40%
#7 PulseChain PulseChain +6.04%
#8 Tutorial Tutorial +5.99%
#9 Xphere Xphere +5.79%
#10 HOME HOME +5.35%
Coin of the day
DogBull DogBull
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Wuhan YZY Biopharma Co Ltd Wuhan YZY Biopharma Co Ltd

Wuhan YZY Biopharma Co Ltd

2496
Clasificación en acciones #22213
Wuhan YZY Biopharma Co., Ltd. is a biotechnology enterprise specializing in the... Wuhan YZY Biopharma Co., Ltd. is a biotechnology enterprise specializing in the development of bispecific antibody-based treatments. Its therapeutic focus areas include various cancers, their associated complications, and age-related ophthalmic conditions. The company's extensive portfolio of drug candidates aims to address a wide range of diseases, such as malignant ascites, malignant pleural effusion, various solid tumors (including pancreatic cancer, hepatocellular carcinoma, other advanced solid tumors, and HER2-positive solid tumors), small cell lung cancer, and relapsed/refractory multiple myeloma. Additionally, they are advancing therapies for COVID-19 and several eye disorders like wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and other conditions characterized by abnormal blood vessel formation in the eye. The company, established in 2010, is headquartered in Wuhan, China.
Precio por acción
$0.46053443
Última sincronización: 2026-08-13
Capitalización bursátil
$92.44M
Cambio (1 día)
0.00%
Cambio (1 año)
-36.86%
País
CN
Comercio Wuhan YZY Biopharma Co Ltd (2496)

Categoría

Healthcare
Ingresos de Wuhan YZY Biopharma Co Ltd (2496)
Ingresos en Aug 2026 TTM: 0
Según los últimos informes financieros de Wuhan YZY Biopharma Co Ltd, los ingresos actuales de la empresa (TTM) son 0. En 2026, la empresa obtuvo unos ingresos de 0 igual a los ingresos del año 2026, que fueron de 0. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de Wuhan YZY Biopharma Co Ltd desde 2026 hasta 2026
Ingresos al final de cada año
Año Ingresos Cambiar
Not enough data for the provided dates.
Ingresos de empresas similares o competidoras
Empresa Ingresos Diferencia de ingresos País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH